Oasis

Oasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of novel small molecule therapeutics for metabolic diseases, including type 2 diabetes and obesity. The company's lead research centers on GPR119 agonists, which aim to stimulate insulin secretion and improve glucose tolerance through a dual mechanism in the pancreas and gut. Oasis is also exploring combination therapies involving SGLT2 inhibitors to provide comprehensive glycemic control. By targeting key metabolic pathways, the company seeks to address the growing global burden of metabolic syndrome and its associated complications.